eyestock logo

eyestock

ON

Onconetix IncNASDAQ ONCO

Последний отчетный период 31 мар., 2024

Обновлено 14 нояб., 2024

Последняя цена

Капитализация млрд. $

0.004

Micro

Биржа

XNAS - Nasdaq

Анализ акций ONCO

ON

Нет оценки

Количественный анализ Eyestock не покрывает акции Onconetix Inc.

Рейтинг

Для оценки качества бизнеса компании мы собрали все финансовые данные из отчетов и представили их в виде одного числа - рейтинга компании. Значение рейтинга 100 является пороговым для определения актуальной инвестиционной идеи.

-61/100

Низкий рейтинг

Капитализация млрд. $

0.004

Дивидендная доходность

Оборот

22.33 млрд

Сайт компании

https://onconetix.gcs-web.com/

Onconetix, Inc. is a commercial stage biotechnology company, which engages in the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The company is headquartered in Cincinnati, Ohio and currently employs 12 full-time employees. The company went IPO on 2022-02-18. The company is focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The company has Entadfi, a Food and Drug Administration approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology. Entadfi is a once-daily, oral treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. Proclarix is a next generation protein-based blood test that can be done with the same sample as a patient’s regular PSA test. Proteomedix is seeking to develop diagnostic, prognostic, and predictive tools to enable cancer management at all stages of disease progression.

Смотреть Секцию: Рейтинг